MCID: ANX010
MIFTS: 73

Anxiety

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Anxiety

MalaCards integrated aliases for Anxiety:

Name: Anxiety 58 12 30 6 44 41 17 74
Anxiety Disorders 56 45 74
Anxiety Disorder 12 15 17
Anxiety State 12 74
Anxiety Neurosis 74

Classifications:



External Ids:

Disease Ontology 12 DOID:2030
OMIM 58 607834
MeSH 45 D001008
NCIt 51 C2878
SNOMED-CT 69 65673007
ICD10 34 F41.8 F41.9
MedGen 43 C0003467

Summaries for Anxiety

OMIM : 58 Human personality is shaped by genetic and environmental factors, and evidence suggests that the genetic component is highly complex, polygenic, and epistatic. Genetic factors are thought to contribute to 40 to 60% of trait variance. Molecular genetics has tried to identify specific genes for quantitative traits, called quantitative trait loci (QTLs). The QTL concept suggests that complex personality traits or dimensions are not attributable to single genes, but to multiple interacting genes (Reif and Lesch, 2003). Fullerton et al. (2003) stated that psychologists were in agreement that the wide variation in human personalities can be explained by a small number of personality factors, including neuroticism (a measure of emotional stability), which manifests at one extreme as anxiety, depression, moodiness, low self-esteem, and diffidence. They cited a number of studies that had described a relationship between high scores on measures of neuroticism and major depressive disorder. They also noted that theoretical studies had suggested that large samples of randomly ascertained sibs could be used to ascertain phenotypically extreme individuals and thereby increase power to detect genetic linkage in complex traits. See also panic disorder (PAND1; 167870), which is a subtype of anxiety disorder. (607834)

MalaCards based summary : Anxiety, also known as anxiety disorders, is related to generalized anxiety disorder and phobic disorder, and has symptoms including agitation, sleeplessness and mental and behavioral signs and symptoms. An important gene associated with Anxiety is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Citalopram and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A cognitive disorder that involves an excessive, irrational dread of everyday situations.

MedlinePlus : 44 Fear and anxiety are part of life. You may feel anxious before you take a test or walk down a dark street. This kind of anxiety is useful - it can make you more alert or careful. It usually ends soon after you are out of the situation that caused it. But for millions of people in the United States, the anxiety does not go away, and gets worse over time. They may have chest pains or nightmares. They may even be afraid to leave home. These people have anxiety disorders. Types include Panic disorder Obsessive-compulsive disorder Post-traumatic stress disorder Phobias Generalized anxiety disorder Treatment can involve medicines, therapy or both. NIH: National Institute of Mental Health

Wikipedia : 77 Anxiety is an emotion characterized by an unpleasant state of inner turmoil, often accompanied by... more...

Related Diseases for Anxiety

Diseases related to Anxiety via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 824)
# Related Disease Score Top Affiliating Genes
1 generalized anxiety disorder 34.4 BDNF COMT CRHR1 HTR1A HTR2A MAOA
2 phobic disorder 33.7 COMT HTR1A MAOA SLC6A4
3 social phobia 33.7 HTR1A MAOA SLC6A4
4 panic disorder 33.4 CCKBR COMT CRH HTR1A HTR2A MAOA
5 agoraphobia 33.1 CCKBR HTR1A MAOA SLC6A4
6 phobia, specific 32.8 COMT MAOA
7 avoidant personality disorder 32.5 MAOA SLC6A4 TPH1
8 fibromyalgia 32.5 COMT CRH HTR2A SLC6A4
9 irritable bowel syndrome 32.5 CRH CRHR1 SLC6A4 TPH1
10 autism spectrum disorder 32.5 BDNF HTR2A SLC6A4 TPH2
11 eating disorder 32.4 BDNF CNR1 COMT CRH HTR2C SLC6A4
12 bipolar disorder 32.4 BDNF COMT HTR1A HTR2A SLC6A4 TPH1
13 bulimia nervosa 32.4 BDNF COMT HTR2A SLC6A4
14 postpartum depression 32.4 BDNF COMT CRH MAOA SLC6A4
15 migraine with or without aura 1 32.2 CNR1 COMT HTR1A HTR2A HTR2C MAOA
16 obsessive-compulsive disorder 32.2 BDNF COMT CRH CYP2D6 HTR1A HTR2A
17 post-traumatic stress disorder 32.2 BDNF CNR1 COMT CRH HTR2A MAOA
18 parkinson disease, late-onset 32.0 BDNF CNR1 COMT CYP2D6 HTR1A HTR2A
19 schizophrenia 31.8 BDNF CNR1 COMT CYP2D6 HTR1A HTR2A
20 depression 31.7 BDNF CRH CRHR1 HTR1A HTR2A HTR2C
21 alexithymia 31.3 COMT HTR1A SLC6A4
22 pain - chronic 31.3 COMT NR3C1
23 personality disorder 31.1 BDNF COMT HTR1A HTR2A HTR2C MAOA
24 anorexia nervosa 31.1 BDNF COMT CRH HTR2A SLC6A4
25 alcohol abuse 31.0 BDNF CNR1 HTR2A SLC6A4
26 substance abuse 30.9 BDNF COMT CYP2D6 MAOA SLC6A4
27 conduct disorder 30.8 COMT MAOA SLC6A4 TPH1
28 dysthymic disorder 30.8 HTR2A MAOA SLC6A4
29 oppositional defiant disorder 30.7 COMT MAOA SLC6A4 TPH2
30 tobacco addiction 30.7 COMT HTR2A MAOA SLC6A4 TPH1
31 premature ejaculation 30.6 HTR1A HTR2C SLC6A4
32 disease of mental health 30.6 BDNF CNR1 COMT CRH CYP2D6 HTR1A
33 mood disorder 30.6 BDNF COMT CRH CRHR1 HTR1A HTR2A
34 attention deficit-hyperactivity disorder 30.6 BDNF COMT CYP2D6 HTR1A HTR2A HTR2C
35 antisocial personality disorder 30.6 COMT MAOA SLC6A4
36 major depressive disorder 30.6 BDNF COMT CRH CRHR1 CYP2D6 HTR1A
37 alcohol dependence 30.5 BDNF CNR1 COMT CRHR1 HTR1A HTR2A
38 amnestic disorder 30.5 BDNF CNR1 HTR1A
39 bipolar i disorder 30.5 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
40 drug dependence 30.4 BDNF CNR1 CRH OPRL1 SLC6A4
41 mental depression 30.4 BDNF COMT CRH CRHR1 CYP2D6 HTR1A
42 schizoaffective disorder 30.4 BDNF COMT HTR2A SLC6A4
43 pathological gambling 30.3 HTR2A MAOA SLC6A4
44 chronic fatigue syndrome 30.3 COMT CRH HTR1A HTR2A MAOA NR3C1
45 borderline personality disorder 30.3 BDNF COMT HTR1A HTR2A HTR2C MAOA
46 psychotic disorder 30.2 BDNF COMT CYP2D6 HTR1A HTR2A HTR2C
47 atypical depressive disorder 30.2 CRH HTR2A MAOA SLC6A4
48 substance dependence 30.2 BDNF CNR1 CYP2D6 MAOA SLC6A4
49 endogenous depression 30.2 BDNF CRH CRHR1 HTR1A HTR2A MAOA
50 paranoid schizophrenia 30.0 BDNF COMT HTR2A MAOA SLC6A4 TPH2

Comorbidity relations with Anxiety via Phenotypic Disease Network (PDN): (show top 50) (show all 80)


Acute Cor Pulmonale Acute Cystitis
Acute Stress Disorder Adjustment Disorder
Allergic Rhinitis Atrophic Gastritis
Atypical Depressive Disorder Basilar Artery Insufficiency
Benign Essential Hypertension Borderline Personality Disorder
Bronchiectasis Bronchitis
Bronchopneumonia Cerebrovascular Disease
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Chronic Rhinitis Conn's Syndrome
Conversion Disorder Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Histrionic Personality Disorder
Hyperlipoproteinemia, Type Iv Hypertension, Essential
Hypertensive Encephalopathy Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome
Hypochondriasis Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Irritable Bowel Syndrome
Ischemic Heart Disease Labyrinthitis
Major Depressive Disorder Malignant Essential Hypertension
Meniere Disease Migraine with or Without Aura 1
Mitral Valve Disease Mood Disorder

Graphical network of the top 20 diseases related to Anxiety:



Diseases related to Anxiety

Symptoms & Phenotypes for Anxiety

Clinical features from OMIM:

607834

UMLS symptoms related to Anxiety:


agitation, sleeplessness, mental and behavioral signs and symptoms, nervousness, feeling tense, feeling jittery, anxiety symptoms

MGI Mouse Phenotypes related to Anxiety:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 BDNF CCKBR CNR1 COMT CRH CRHR1
2 homeostasis/metabolism MP:0005376 10.21 BDNF CCKBR CNR1 COMT CRH CRHR1
3 nervous system MP:0003631 10.1 BDNF CCKBR CNR1 COMT CRH CRHR1
4 cardiovascular system MP:0005385 10.06 CCKBR COMT CRHR1 HTR1A MAOA NR3C1
5 integument MP:0010771 10.02 BDNF CCKBR CNR1 CRH HTR2C NR3C1
6 adipose tissue MP:0005375 9.93 CNR1 CRH HTR2C NR3C1 TPH1 TPH2
7 no phenotypic analysis MP:0003012 9.7 BDNF CNR1 CRH CRHR1 HTR1A NR3C1
8 normal MP:0002873 9.56 BDNF CNR1 CRH CRHR1 NR3C1 OPRL1
9 respiratory system MP:0005388 9.17 BDNF COMT CRH CRHR1 NR3C1 TPH1

Drugs & Therapeutics for Anxiety

Drugs for Anxiety (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1283)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
2
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 99-66-1 3121
3
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
4
Vortioxetine Approved, Investigational Phase 4,Phase 3,Phase 2 508233-74-7 9966051
5
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10024-97-2 948
6
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6740-88-1 3821
7
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59467-70-8 4192
8
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 113775-47-6 5311068 68602
9
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
10
Buspirone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36505-84-7 2477
11
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2078-54-8 4943
12
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 846-49-1 3958
13
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 57-27-2 5288826
14
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 79617-96-2 68617
15
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54910-89-3 3386
16
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 54739-18-3 5324346 3404
17
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6, 15438-31-0 27284 23925
18
Donepezil Approved Phase 4,Phase 3,Phase 2,Not Applicable 120014-06-4 3152
19
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 68-04-2
20
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
21
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
22
Rocuronium Approved Phase 4,Phase 3,Not Applicable 119302-91-9, 143558-00-3 441290
23
Sufentanil Approved, Investigational Phase 4,Phase 2,Not Applicable 56030-54-7 41693
24
Etomidate Approved Phase 4 33125-97-2 667484 36339
25
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
26
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 27203-92-5 33741
27
Trimebutine Approved Phase 4 39133-31-8
28
Rabeprazole Approved, Investigational Phase 4,Not Applicable 117976-89-3 5029
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 437-38-7 3345
30
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 439-14-5 3016
31
Dronabinol Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1972-08-3 16078
32
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-03-3
33
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-23-7 5754
34
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-56-6 53477758 439302
35
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 616-91-1 12035
36
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
37
Drospirenone Approved Phase 4 67392-87-4 68873
38
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 50-28-2 5757
39
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 28014-46-2
40
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 113-45-1 4158
41
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
42
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
43
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
44
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
45
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 60142-96-3 3446
46
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6 774
47
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
48
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85650-52-8, 61337-67-5 4205
49
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 146939-27-7 60854
50
Lithium carbonate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 554-13-2

Interventional clinical trials:

(show top 50) (show all 10141)
# Name Status NCT ID Phase Drugs
1 Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
2 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Unknown status NCT02777905 Phase 4
3 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
4 The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung Unknown status NCT01362114 Phase 4 SIHOGAYONGGOLMORYU TANG EXTRACT GRAN
5 Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children Unknown status NCT02545634 Phase 4
6 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4 Pregabalin;Placebo
7 Preoperative Anxiety and Postoperative Pain in Children Unknown status NCT00643032 Phase 4
8 Effect of Music Over the Tolerance to Colonoscopy. Unknown status NCT01285284 Phase 4
9 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
10 Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Double-blind Randomized Controlled Trial Unknown status NCT02243826 Phase 4 50:50 mixture of nitrous oxide/oxygen
11 Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients Unknown status NCT03043430 Phase 4 Ketamine 100 MG/ML;Midazolam 5 MG/ML
12 A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children Unknown status NCT02459509 Phase 4 Dexmedetomidine
13 Assessment of the Effectiveness of a Program of Preparation to Pregnancy and Delivery Unknown status NCT01155804 Phase 4
14 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
15 Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Anxious Patients Unknown status NCT00355693 Phase 4
16 Oral Midazolam for Sedation in Esophagogastroduodenoscopy(EGD) Unknown status NCT01990937 Phase 4 Oral midazolam
17 Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy Unknown status NCT01121055 Phase 4 Lorazepam;Control
18 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
19 MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial) Unknown status NCT02856698 Phase 4 Midazolam;Morphine
20 Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients Unknown status NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
21 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
22 Anemia in Inflammatory Bowel Disease Unknown status NCT02760940 Phase 4 oral liposomal iron
23 A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease Unknown status NCT03151382 Phase 4 Tandospirone Citrate;Donepezil Hydrochloride
24 Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause Unknown status NCT01116310 Phase 4 Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L);Placebo
25 Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients Unknown status NCT02134093 Phase 4 Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium;Dexmedetomidine;Normal saline;Maintenance of anesthesia , propofol, remifentanil,vecuronium
26 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4 Tramadol;Placebo
27 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Unknown status NCT01606111 Phase 4 Cerebrolysin;0.9% NaCl, saline
28 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
29 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
30 Randomised Controlled Study of Popofol Versus Midazolam as Sedation in Endoscopy With Advanced Liver Disease. Unknown status NCT03063866 Phase 4 Propofol;Midazolam;Fentanyl
31 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
32 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
33 Prevention of Posttraumatic Stress Disorder (PTSD) With Diazepam Unknown status NCT01221883 Phase 4 Diazepam
34 Customized Acoustic Stimulation for Long Term Medical Benefit for the Relief of Tinnitus and Hyperacusis Unknown status NCT00730834 Phase 4
35 The ED50 of DEX for Providing Sedation in Different Female Age Group Unknown status NCT02773017 Phase 4 Dexmedetomidine A;Dexmedetomidine B;Dexmedetomidine C
36 Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
37 Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD) Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
38 Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
39 Impact of Probiotic Preparation VSL#3 on Infants Colics Unknown status NCT01869426 Phase 4
40 Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy Unknown status NCT02900755 Phase 4 Perampanel
41 The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD) Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO
42 Vitamin D Supplementations and Postoperative Pain Unknown status NCT02664857 Phase 4 Vitamin D;Placebo
43 The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms Unknown status NCT00866866 Phase 4 N-Acetyl Cysteine;Placebo
44 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
45 Climacteric Clinical Trial : the Use of Complementary Therapy and Hormonal Replacement Unknown status NCT00617500 Phase 4 Hormones
46 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4 METHYLPHENIDATE
47 Study of the Safety and Efficacy of Botox in Bruxism Unknown status NCT00908050 Phase 4 Botulinum toxin type A
48 Pregabalin for Alcohol Dependence Unknown status NCT02205879 Phase 4 Pregabalin;Placebo
49 Ultrasound Guided Cannulation of Dialysis Fistulas Unknown status NCT01163981 Phase 4
50 Paracervical Block for Pain Control in First Trimester Abortion Unknown status NCT01094366 Phase 4

Search NIH Clinical Center for Anxiety

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: anxiety disorders

Genetic Tests for Anxiety

Genetic tests related to Anxiety:

# Genetic test Affiliating Genes
1 Anxiety 30 SLC6A4

Anatomical Context for Anxiety

MalaCards organs/tissues related to Anxiety:

42
Brain, Breast, Testes, Heart, Prostate, Lung, Amygdala

Publications for Anxiety

Articles related to Anxiety:

(show top 50) (show all 14513)
# Title Authors Year
1
The incidence of anxiety symptoms in boys with 47,XXY (Klinefelter syndrome) and the possible impact of timing of diagnosis and hormonal replacement therapy. ( 30637954 )
2019
2
Evaluating the effect of lifestyle education based on peer model on anxiety in patients with acute myocardial infarction. ( 30661058 )
2019
3
Efficacy and feasibility of a humor training for people suffering from depression, anxiety, and adjustment disorder: a randomized controlled trial. ( 30894148 )
2019
4
Relationship between induced abortion and the incidence of depression, anxiety disorder, adjustment disorder, and somatoform disorder in Germany. ( 31048110 )
2019
5
Anxiety and task performance changes in an aging mouse model. ( 31029428 )
2019
6
Ageism in an Aging Society: The Role of Knowledge, Anxiety about Aging, and Stereotypes in Young People and Adults. ( 31013873 )
2019
7
FAAH genotype, CRFR1 genotype, and cortisol interact to predict anxiety in an aging, rural Hispanic population: A Project FRONTIER study. ( 30949563 )
2019
8
The Relative Contributions of Cell-Dependent Cortical Microcircuit Aging to Cognition and Anxiety. ( 30446205 )
2019
9
Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes. ( 30718541 )
2019
10
Internet gaming disorder in male and female young adults: The role of alexithymia, depression, anxiety and gaming type. ( 30616119 )
2019
11
The role of long-term psychodynamic psychotherapy in improving attachment patterns, defense styles, and alexithymia in patients with depressive/anxiety disorders. ( 30994785 )
2019
12
Factors associated with the adults' attachment styles in Lebanon: The role of alexithymia, depression, anxiety, stress, burnout, and emotional intelligence. ( 31004358 )
2019
13
Alexithymia in individuals with chronic pain and its relation to pain intensity, physical interference, depression, and anxiety: a systematic review and meta-analysis. ( 31009416 )
2019
14
Influence of anxiety and alexithymia on brain activations associated with the perception of others' pain in autism. ( 29683406 )
2019
15
HrQoL in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety. ( 30394586 )
2019
16
Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series. ( 30681431 )
2019
17
A systematic review of studies probing longitudinal associations between anxiety and anorexia nervosa. ( 31096148 )
2019
18
Ethnic variance between Asian and European American women in a six month prospective model of eating disorder and social anxiety symptom comorbidity. ( 31084428 )
2019
19
Altitude and risk of depression and anxiety: findings from the intern health study. ( 31084447 )
2019
20
Increased anxiety and decreased sociability induced by paternal deprivation involve the PVN-PrL OTergic pathway. ( 31084703 )
2019
21
Auditory perceptual learning is not affected by anticipatory anxiety in the healthy population except for highly anxious individuals: EEG evidence. ( 31085447 )
2019
22
Correlation between Internet addiction, depression, anxiety and stress among undergraduate medical students in Azad Kashmir. ( 31086541 )
2019
23
Association of hearing loss with depression, anxiety and stress in patients suffering from Chronic Suppurative Otitis Media. ( 31086542 )
2019
24
The Effects of Youth Anxiety Treatment on School Impairment: Differential Outcomes Across CBT, Sertraline, and their Combination. ( 31087216 )
2019
25
Separation anxiety: Extreme dehiscence of a mitral annuloplasty ring. ( 31087390 )
2019
26
A systematic review on the prevalence of symptoms of depression, anxiety and distress in long-term cancer survivors: Implications for primary care. ( 31087398 )
2019
27
The effects of childhood inattention and anxiety on executive functioning: inhibition, updating, and shifting. ( 31089961 )
2019
28
Social Withdrawal and Anxiety in Childhood and Adolescence: Interaction between Individual Tendencies and Interpersonal Learning Mechanisms in Development : Introduction to the Special Section. ( 31089980 )
2019
29
Cutoff of the Zarit Burden Interview in predicting depression and anxiety. ( 31089989 )
2019
30
Establishing a common metric for self-reported anxiety in patients with prostate cancer: Linking the Memorial Anxiety Scale for Prostate Cancer with PROMIS Anxiety. ( 31090933 )
2019
31
The 5-Year Course of Medication Treatment in Childhood Anxiety Disorders. ( 31091028 )
2019
32
Pregnancy-specific anxiety and elective cesarean section in primiparas: A cohort study in China. ( 31091276 )
2019
33
Influence of Anxiety/Depression on the Subjective Evaluation of Cough in Patients with Chronic Obstructive Pulmonary Disease and Obesity. ( 31091811 )
2019
34
Validity and reliability of the Turkish version of the modified Yale Preoperative Anxiety Scale ( 31091856 )
2019
35
Improvement of Urinary Incontinence, Life Impact, and Depression and Anxiety With Modified Pelvic Floor Muscle Training After Radical Prostatectomy. ( 31092098 )
2019
36
Examining the effectiveness of a web-based intervention for symptoms of depression and anxiety in college students: study protocol of a randomised controlled trial. ( 31092668 )
2019
37
Treating Anxiety and Social Deficits in Children with Autism Spectrum Disorder in Two Schools in Nairobi, Kenya. ( 31093801 )
2019
38
Potential Role of Vitamin D for the Management of Depression and Anxiety. ( 31093951 )
2019
39
Internet-Based Cognitive Therapy for Social Anxiety Disorder in Hong Kong: Therapist Training and Dissemination Case Series. ( 31094320 )
2019
40
Benefit of Watching a Live Visual Inspection of the Cervix With Acetic Acid and Lugol Iodine on Women's Anxiety: Randomized Controlled Trial of an Educational Intervention Conducted in a Low-Resource Setting. ( 31094335 )
2019
41
The relationship between pain at IUD insertion and negative perceptions, anxiety and previous mode of delivery. ( 31094575 )
2019
42
Does Anxiety Affect Neuropsychological Assessment in Collegiate Athletes. ( 31094613 )
2019
43
Death anxiety, perceived social support, and demographic correlates of patients with breast cancer in Pakistan. ( 31094668 )
2019
44
Longitudinal Associations of Self-reported Vision Impairment With Symptoms of Anxiety and Depression Among Older Adults in the United States. ( 31095253 )
2019
45
Bidirectionality of the Association of Vision Impairment With Depression and Anxiety. ( 31095254 )
2019
46
Attentional Control Explains Covariation Between Symptoms of Attention-Deficit/Hyperactivity Disorder and Anxiety During Adolescence. ( 31095814 )
2019
47
Nucleus accumbens shell small conductance potassium channels underlie adolescent ethanol exposure-induced anxiety. ( 31096263 )
2019
48
Internet Interventions for Adults with Anxiety and Mood Disorders: A Narrative Umbrella Review of Recent Meta-Analyses. ( 31096757 )
2019
49
Association of State and Trait Anxiety Between Patients Who Had Undergone Traumatic Amputation and Their Family Caregivers. ( 31096796 )
2019
50
Convergent neurobiological predictors of mood and anxiety symptoms and treatment response. ( 31096806 )
2019

Variations for Anxiety

ClinVar genetic disease variations for Anxiety:

6 (show all 16)
# Gene Variation Type Significance SNP ID Assembly Location
1 USH2A NM_206933.2(USH2A): c.2299delG (p.Glu767Serfs) deletion Pathogenic/Likely pathogenic rs80338903 GRCh37 Chromosome 1, 216420437: 216420437
2 USH2A NM_206933.2(USH2A): c.2299delG (p.Glu767Serfs) deletion Pathogenic/Likely pathogenic rs80338903 GRCh38 Chromosome 1, 216247095: 216247095
3 46;XY;t(6;12)(q14;q24);20p+dn complex Pathogenic
4 46;XX;t(2;11)(q11.2;p13)dn Translocation Pathogenic
5 46;XY;t(2;6)(q33;q21)dn Translocation Pathogenic
6 46;XY;t(1;2)(p34.2;q35)dn Translocation Pathogenic
7 HMBS NM_000190.3(HMBS): c.958delG (p.Ala320Leufs) deletion Likely pathogenic rs1057518806 GRCh37 Chromosome 11, 118963865: 118963865
8 HMBS NM_000190.3(HMBS): c.958delG (p.Ala320Leufs) deletion Likely pathogenic rs1057518806 GRCh38 Chromosome 11, 119093155: 119093155
9 OTX2 NM_172337.2(OTX2): c.167_169delTGTinsGG (p.Leu56Argfs) indel Likely pathogenic rs1555350397 GRCh38 Chromosome 14, 56804268: 56804270
10 OTX2 NM_172337.2(OTX2): c.167_169delTGTinsGG (p.Leu56Argfs) indel Likely pathogenic rs1555350397 GRCh37 Chromosome 14, 57270986: 57270988
11 ADAR NM_001193495.2(ADAR): c.761C> A (p.Ala254Asp) single nucleotide variant Uncertain significance GRCh37 Chromosome 1, 154571017: 154571017
12 ADAR NM_001193495.2(ADAR): c.761C> A (p.Ala254Asp) single nucleotide variant Uncertain significance GRCh38 Chromosome 1, 154598541: 154598541
13 USH2A NM_206933.3(USH2A): c.5003G> T (p.Gly1668Val) single nucleotide variant Uncertain significance GRCh37 Chromosome 1, 216258204: 216258204
14 USH2A NM_206933.3(USH2A): c.5003G> T (p.Gly1668Val) single nucleotide variant Uncertain significance GRCh38 Chromosome 1, 216084862: 216084862
15 MYH8 NM_002472.3(MYH8): c.5743A> G (p.Ile1915Val) single nucleotide variant Uncertain significance GRCh37 Chromosome 17, 10293842: 10293842
16 MYH8 NM_002472.3(MYH8): c.5743A> G (p.Ile1915Val) single nucleotide variant Uncertain significance GRCh38 Chromosome 17, 10390525: 10390525

Copy number variations for Anxiety from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 139649 2 185171337 185512459 Deletion ZNF804A anxiety disorder

Expression for Anxiety

Search GEO for disease gene expression data for Anxiety.

Pathways for Anxiety

Pathways related to Anxiety according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.3 CCKBR CNR1 CRH CRHR1 HTR1A HTR2A
2
Show member pathways
12.84 BDNF CNR1 CRH CRHR1 HTR2A HTR2C
3 12.39 CNR1 COMT HTR1A TPH1 TPH2
5 11.97 BDNF HTR1A HTR2A MAOA NR3C1 SLC6A4
6
Show member pathways
11.81 COMT CYP2D6 SLC6A4
7
Show member pathways
11.78 HTR1A HTR2A HTR2C
8 11.74 CCKBR CNR1 HTR2A
9 11.62 CYP2D6 HTR1A HTR2A HTR2C MAOA SLC6A4
10
Show member pathways
11.24 MAOA SLC6A4 TPH2
11
Show member pathways
11.01 COMT MAOA SLC6A4
12
Show member pathways
10.89 COMT MAOA TPH1
13 10.88 HTR2A HTR2C
14
Show member pathways
10.69 COMT MAOA
15 10.68 COMT MAOA
16 10.64 CCKBR CNR1
17 10.61 HTR1A HTR2A HTR2C MAOA SLC6A4 TPH1
18 10.32 CRH CRHR1

GO Terms for Anxiety

Cellular components related to Anxiety according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.7 CNR1 CRHR1 HTR1A HTR2A HTR2C OPRL1
2 dendrite GO:0030425 9.35 BDNF COMT HTR1A HTR2A HTR2C
3 integral component of presynaptic membrane GO:0099056 8.8 CNR1 HTR2A SLC6A4

Biological processes related to Anxiety according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.91 CRH HTR1A HTR2A HTR2C
2 response to drug GO:0042493 9.88 COMT CRH HTR2A HTR2C SLC6A4
3 G protein-coupled receptor signaling pathway GO:0007186 9.81 CCKBR CNR1 CRH CRHR1 HTR1A HTR2A
4 female pregnancy GO:0007565 9.8 COMT CRH CRHR1
5 circadian rhythm GO:0007623 9.79 SLC6A4 TPH1 TPH2
6 response to estrogen GO:0043627 9.74